ADAM8 as a novel serological and histochemical marker for lung cancer

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8363-8370

  Ishikawa, Nobuhisa ^a,b   Daigo, Yataro ^a   Yasui, Wataru ^b   Inai, Kouki ^b   Nishimura, Hitoshi ^c   Tsuchiya, Eiju ^d   Kohno, Nobuoki ^b   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d KANAGAWA CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DISINTEGRIN; PROTEIN ADAM8; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CELL INVASION; CELL STRAIN 3T3; CELL STRAIN COS7; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY;

ADAM PROTEINS; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELL MOVEMENT; CERCOPITHECUS AETHIOPS; COLLAGEN; COS CELLS; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LAMININ; LUNG; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; METALLOENDOPEPTIDASES; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; NIH 3T3 CELLS; PROGNOSIS; PROTEOGLYCANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEROLOGY; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 11144240470     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1436     Document Type: Article

References (24)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA - Cancer J Clin 2000;50(1):7-33.
2. Naruke T, Tsuchiya R, Kondo H, Asamura H. Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001;71(6):1759-64.
3. Shinkai T, Saijo N, Tominaga K, et al. Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy. Cancer (Phila.) 1986;57(7):1318-23.
4. Pujol JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 1993;53(1): 61-6.
5. Miyake Y, Kodama T, Yamaguchi K. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. Cancer Res 1994;54(8):2136-40.
6. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003;22(14):2192-205.
7. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res 2003;63(21):7038-41.
8. Yoshiyama K, Higuchi Y, Kataoka M, Matsuura K, Yamamoto S. CD156 (human ADAM8): expression, primary amino acid sequence, and gene location. Genomics 1997;41(1):56-62.
9. Yamamoto S, Higuchi Y, Yoshiyama K, et al. ADAM family proteins in the immune system. Immunol Today 1999;20(6):278-84.
10. Schlomann U, Wildeboer D, Webster A, et al. The metalloprotease disintegrin ADAM8. Processing by autocatalysis is required for proteolytic activity and cell adhesion. Biol Chem 2002;277(50): 48210-9.
11. Primakoff P, Myles DG. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 2000;16(2):83-7.
12. Seals DF, Courtneidge SA. The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev 2003;17(1):7-30.
13. Fourie AM, Coles F, Moreno V, Karlsson L. Catalytic activity of ADAM8, ADAM15, and MDC-L (ADAM28) on synthetic peptide substrates and in ectodomain cleavage of CD23. J Biol Chem 2003;278(33):30469-77.
14. Naus S, Richter M, Wildeboer D, Moss M, Schachner M, Bartsch JW. Ectodomain shedding of the neural recognition molecule CHL1 by the metalloprotease-disintegrin ADAM8 promotes neurite outgrowth and suppresses neuronal cell death. J Biol Chem 2004;279(16): 16083-90.
15. Karan D, Lin FC, Bryan M, et al. Expression of ADAMs (a disintegrin and metalloproteases) and TIMP-3 (tissue inhibitor of metalloproteinase-3) in human prostatic adenocarcinomas. Int J Oncol 2003;23(5):1365-71.
16. O'Shea C, McKie N, Buggy Y, et al. Expression of ADAM-9 mRNA and protein in human breast cancer. Int J Cancer 2003;105(6): 754-61.
17. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4(7):844-7.
18. Chin SF, Daigo Y, Huang HE, et al. A simple and reliable pretreatment protocol facilitates fluorescent in situ hybridisation on tissue microarrays of paraffin wax embedded tumour samples. Mol Pathol 2003;56(5):275-9.
19. Callagy G, Cattaneo E, Daigo Y, et al. Molecular classification of breast carcinomas using tissue microarrays. Diagn Mol Pathol 2003;12(1):27-34.
20. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346(2):92-8.
21. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19(13): 3210-8.
22. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol 2004;5(6):341-53.
23. Michael M, Babic B, Khokha R, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol 1999;17(6): 1802-8.
24. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111(6):1710-7.